🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchSurvodutide (GCG/GLP-1) — MASH and obesity trial results Page 4

Survodutide (GCG/GLP-1) — MASH and obesity trial results

MASHdoc_SA Sat, Jun 6, 2026 at 8:40 PM 16 replies 467 viewsPage 4 of 4
Dr.GastroMayo
VIP Member
2,345
13,456
Jan 2024
Mayo Clinic, MN
Jun 8, 2026 at 8:27 AM#16
GenomicsKate said:
The version of this that has an answer is narrower than the version being asked.

Second this.

28 3mike_nyc, VendorMark, COA_Karl and 25 others
Reply Quote Save Share Report
Dr.NutriCornell
Senior Member
1,345
6,234
Mar 2024
Ithaca, NY
Jun 8, 2026 at 11:19 AM#17
PharmacoVig_BOS said:
If you are going to change something, change one thing and give it long enough to express itself.

Saving this. It is the first explanation that did not require me to already understand it. I will report back once I have actually tried it.

27 2Dr.SleepRoch, laura_annarbor, JenMemphis and 24 others
Reply Quote Save Share Report
julia.endo
Senior Member
1,890
9,012
Feb 2024
Cincinnati, OH
Jun 8, 2026 at 2:10 PM#18

Adding the clinical framing, because it changes how the question reads. If two explanations both fit, the useful question is which one predicts something the other does not. That is answerable; arguing about which sounds more plausible is not.

Worth separating that from liver and MASH, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

26 1hans_munich, jason_sac26, chris_chi24 and 23 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
raj_cambridge
Member
489
2,123
Jun 2024
Cambridge, MA
Jun 8, 2026 at 5:02 PM#19
julia.endo said:
If two explanations both fit, the useful question is which one predicts something the other does not.

Same experience, arrived at from the opposite direction. Nothing to add that would improve it.

25 0PharmHunterJen, TomTeleRx, DoseLogDan and 22 others
Reply Quote Save Share Report
Admin
Administrator
2,456
9,812
Oct 2023
Online
Jun 8, 2026 at 7:54 PM#20

Moderator note: the sourcing question belongs in the vendor section and has been split out.

Last edited: Jun 8, 2026 at 11:54 PM
3 3PeptideSynthNJ, Dr.KarenChen, Dr.NateNeph
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register